GSK announced it has signed agreements with the Government of Canada to supply 20,000 doses of Sotrovimab for injection. Sotrovimab is a COVID-19 monoclonal antibody therapy developed by GSK and Vir Biotechnology. This follows the initial purchase agreement with the Government of Canada to supply 10,000 doses of Sotrovimab, announced on October 4, 2021.

That agreement included the option for the Government of Canada to purchase additional doses based on emerging needs. As per GSK's first contract, this agreement was negotiated with Public Services and Procurement Canada and the Public Health Agency of Canada. It enables provincial and territorial healthcare systems to access Sotrovimab immediately to treat patients with mild to moderate COVID-19 symptoms who are at high risk for progressing to hospitalization or death, such as older adults and individuals with certain chronic medical conditions.

In fact, a portion of these 20,000 doses has already been distributed to provinces equipping them with therapeutics to treat COVID-19 patients.